Breast Cancer Research and Treatment

, Volume 122, Issue 2, pp 585–590 | Cite as

Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy

  • Anne H. Blaes
  • Philippe Gaillard
  • Bruce A. Peterson
  • Douglas Yee
  • Beth Virnig
Brief Report


Doxorubicin (DOX), despite causing cardiac toxicity, is an anthracycline chemotherapeutic agent that plays an important role in the treatment of breast cancer. Angiotensin-converting enzyme inhibitors (ACE-I) may protect against cardiac toxicity in patients receiving DOX chemotherapy. A total of 143 patients receiving DOX at the Masonic Comprehensive Cancer Clinic, University of Minnesota, who had two or more multigated blood pool imaging (MUGA) scans or echocardiograms performed between 2004 and 2007 were identified and reviewed. Patients with a 10% absolute drop in their ejection fraction (EF) or more to below 55% were identified and compared with those that did not have a 10% decline in EF. Impact of patient variables and the use of concurrent medications on EF drop were evaluated using logistic regression. Median age was 52 years old. 85 (60%) were female. Cancer diagnosis was breast (n = 26), lymphoma (n = 92), and other (n = 25). In spite of a similar baseline EF in all the patients, 22/142 (15%) patients had a significant drop in EF during DOX chemotherapy. Adjusting for age, the odds ratio of EF drop associated with the use of ACE-I is 0.267 (P = 0.0940), suggesting that ACE-I has a protective effect. Cumulative DOX dose, the use of beta-blockers, or aspirin did not appear to be predictive or protective. Although not statistically significant, this study suggests that the use of ACE-I when given with DOX chemotherapy protects against DOX chemotherapy and warrants further investigation.


Doxorubicin Cardiomyopathy Chemotherapy Predictors Angiotensin converting enzyme inhibitors 



This article was supported by NRSA T32-HL07062-31.


  1. 1.
    Lopez M, Vici P, Di Lauro K et al (1998) Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16:86–92PubMedGoogle Scholar
  2. 2.
    Moore S (2001) Drug-induced congestive heart failure in breast cancer survivors. Clin Excell Nurse Pract 5:129–133CrossRefPubMedGoogle Scholar
  3. 3.
    Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792CrossRefPubMedGoogle Scholar
  4. 4.
    Machida U, Kami M, Hirai H (1998) Treatment of intermediate-grade and high-grade non-hodgkin’s lymphoma. N Engl J Med 339:1476Google Scholar
  5. 5.
    Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242CrossRefPubMedGoogle Scholar
  6. 6.
    Akhtar S, Maghfoor I (2002) Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med 346:1830–1831CrossRefPubMedGoogle Scholar
  7. 7.
    Swain SM (1999) Doxorubicin-induced cardiomyopathy. N Engl J Med 340:654PubMedGoogle Scholar
  8. 8.
    Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900–905CrossRefPubMedGoogle Scholar
  9. 9.
    Lefrak EA, Pitha J, Rosenheim S et al (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32(3):302–314CrossRefPubMedGoogle Scholar
  10. 10.
    Hayek ER, Speakman E, Rehmus E (2005) Acute doxorubicin cardiotoxicity. N Engl J Med 352:2456–2457CrossRefPubMedGoogle Scholar
  11. 11.
    McKillop J, Bristow M, Goris M et al (1983) Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 106:1048–1056CrossRefPubMedGoogle Scholar
  12. 12.
    Ritchie J, Singer J, Thorning D (1980) Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer 46:1109–1116CrossRefPubMedGoogle Scholar
  13. 13.
    Paulides M, Kremers A, Stohr W et al (2006) Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer 46(4):489–495CrossRefPubMedGoogle Scholar
  14. 14.
    Bleyer WA (1990) The impact of childhood cancer on the United States and the world. CA Cancer J Clin 40:355–367CrossRefPubMedGoogle Scholar
  15. 15.
    Hershman DL, McBride RB, Eisenberger A et al (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol 26(19):3159–3165CrossRefPubMedGoogle Scholar
  16. 16.
    Coccaro M, Gallucci G (2008) Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer. J Clin Oncol 26(19):3288CrossRefPubMedGoogle Scholar
  17. 17.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717CrossRefGoogle Scholar
  18. 18.
    Boucek RJ Jr, Steele A, Miracle A et al (2003) Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol 3:319–329CrossRefPubMedGoogle Scholar
  19. 19.
    Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474–2481CrossRefPubMedGoogle Scholar
  20. 20.
    Granger CB (2006) Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done? Circulation 114:2432–2433CrossRefPubMedGoogle Scholar
  21. 21.
    Hatake K, Miura Y (1996) Angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 347:1485CrossRefPubMedGoogle Scholar
  22. 22.
    Iqbal M, Dubey K, Anwer T (2008) Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 60(3):382–390PubMedGoogle Scholar
  23. 23.
    Dunn FG, Oigman W, Ventura HO et al (1984) Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 53:105–108CrossRefPubMedGoogle Scholar
  24. 24.
    Wang LX, Ideishi M, Yahiro E et al (2001) Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury. Hypertens Res 24:179–187CrossRefPubMedGoogle Scholar
  25. 25.
    Ibrahim MA, Ashour OM, Ibrahim YF et al (2009) Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 60:373–381CrossRefPubMedGoogle Scholar
  26. 26.
    Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA (2001) Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 414:71–78CrossRefPubMedGoogle Scholar
  27. 27.
    Iqbal M, Dubey K, Anwer T, Ashish A, Pillai K (2008) Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Res 60:382–390Google Scholar
  28. 28.
    Toko H, Oka T, Zou Y, Sakamoto M et al (2002) Angiotensin II type Ia receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 25:597–603CrossRefPubMedGoogle Scholar
  29. 29.
    Seidman A, Hudis C, Pierri MK et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20(5):1215–1221CrossRefPubMedGoogle Scholar
  30. 30.
    Swain S, Whaley F, Gerber M et al (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1332Google Scholar
  31. 31.
    Seymour L, Bramwell V, Moran LA (1999) Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. Cancer Prev Control 3(2):145–159PubMedGoogle Scholar
  32. 32.
    Nakamae H, Tsumura K, Terada Y et al (2005) Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104:2492–2498CrossRefPubMedGoogle Scholar
  33. 33.
    Jensen BV, Skovsgaard T, Nielsen SL (2002) Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13(5):699–709CrossRefPubMedGoogle Scholar
  34. 34.
    Kalay N, Basar E, Ozdogru I et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48(11):2258–2262CrossRefPubMedGoogle Scholar
  35. 35.
    Sardão VA, Oliveira PJ, Holy J et al (2009) Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemother Pharmacol 64(4):811–827CrossRefPubMedGoogle Scholar
  36. 36.
    Fazio S, Palmieri EA, Ferravante B et al (1998) Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol 21(10):777–779CrossRefPubMedGoogle Scholar
  37. 37.
    Tallaj JA, Franco V, Rayburn BK et al (2005) Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 24(12):2196–2201CrossRefPubMedGoogle Scholar
  38. 38.
    Naidu MU, Kumar KV, Mohan IK et al (2002) Protective effect of Gingko biloba extract against doxorubicin-induced cardiotoxicity in mice. Indian J Exp Biol 40(8):894–900PubMedGoogle Scholar
  39. 39.
    Sung RY, Huang GY, Shing MK et al (1997) Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int J Cardiol 60(3):239–248CrossRefPubMedGoogle Scholar
  40. 40.
    Steinherz LJ, Steinherz PG, Tan CT et al (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266(12):1672–1677CrossRefPubMedGoogle Scholar
  41. 41.
    Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431–1439CrossRefPubMedGoogle Scholar
  42. 42.
    Meinardi MT, van Veldhuisen DJ, Gietema JA et al (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19(10):2746–2753PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Anne H. Blaes
    • 1
  • Philippe Gaillard
    • 2
  • Bruce A. Peterson
    • 1
  • Douglas Yee
    • 1
  • Beth Virnig
    • 3
  1. 1.Department of Medicine, Division of Hematology/Oncology/TransplantationUniversity of MinnesotaMinneapolisUSA
  2. 2.School of Public Health, Division of BiostatisticsUniversity of MinnesotaMinneapolisUSA
  3. 3.School of Public Health, Division of Health Policy and ManagementUniversity of MinnesotaMinneapolisUSA

Personalised recommendations